Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsCompany reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersNEW YORK, March 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANCE. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of ShareholdersNEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Beacon Roofing Supply, Inc. (Nasdaq – BECN), Optinose, Inc. (Nasdaq – OPTN), Corporation (Nasdaq – RDFN), Blackboxstocks Inc. (Nasdaq – BLBX)BALA CYNWYD, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
OPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Optinose, Inc. (
NASDAQ: OPTN) to Paratek Pharmaceuticals is fair to Optinose shareholders. Under the terms of the proposed transaction, Paratek will acquire Optinose for $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANCE.
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating Optinose (
NASDAQ:OPTN) for possible breaches of fiduciary duty and other violations of law in its transaction with Paratek.
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings CallYARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionPreliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%
Optinose Announces 1-for-15 Reverse Stock SplitYARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (
NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading symbol “OPTN.”
Optinose to Present at the Piper Sandler 36th Annual Healthcare ConferenceYARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 1:30 p.m. ET.
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational HighlightsCompany reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023
Optinose Announces Reporting Date for Third Quarter 2024 Financial ResultsConference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 185,000 shares of its common stock to eight new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Optinose Appoints Terry Kohler as Chief Financial OfficerYARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer.
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus SurgeryYARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society.
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceYARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational HighlightsCompany reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023
Optinose Announces Reporting Date for Second Quarter 2024 Financial ResultsConference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time
Expanded Access to XHANCE with Addition to National Commercial FormulariesYARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE® (fluticasone propionate) has been added to Express Scripts’ national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives.
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQYARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (
NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.
Optinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsCompany reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023
Optinose Announces Reporting Date for First Quarter 2024 Financial ResultsConference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time
Optinose Announces $55 Million Registered Direct OfferingLed by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors
